SCHEMBL10399412

SCHEMBL10399412

CC(=O)N(CCc1ccc(F)cc1)Cc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.56
KDM4E B2RXH2 2/20 0.56
GAA P10253 1/20 0.56
RCE1 Q9Y256 1/20 0.52
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
RAB9A P51151 2/20 0.51
CA12 O43570 3/20 0.51
CA1 P00915 3/20 0.51
CA2 P00918 3/20 0.51
CA4 P22748 3/20 0.51
LPAR1 Q92633 3/20 0.50
LPAR5 Q9H1C0 3/20 0.50
MCHR1 Q99705 1/20 0.49
MAPT P10636 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
APAF1 O14727 1/20 0.48
ALDH1A1 P00352 1/20 0.48
HTT P42858 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6411621 0.93 LMNA (0.50) LMNAKDM4EGAAMEN1KMT2A
SCHEMBL2186353 0.91 RCE1 (0.56) LMNAKDM4ERCE1MEN1KMT2A
SCHEMBL6901088 0.86 RCE1 (0.53) KDM4ERCE1MEN1KMT2ARAB9A
SCHEMBL10398283 0.86 RCE1 (0.53) RCE1MEN1KMT2ARAB9ACA12
SCHEMBL6414968 0.86 MCHR1 (0.51) LMNAMEN1KMT2ARAB9ACA12
SCHEMBL6415124 0.85 SLC2A4 (0.47) LMNAKDM4EGAAMCHR1MAPT
SCHEMBL10399236 0.85 CA12 (0.55) LMNAKDM4EGAARCE1MEN1
SCHEMBL10399486 0.85 RCE1 (0.52) LMNARCE1MEN1KMT2ARAB9A
SCHEMBL14544524 0.82 LPAR1 (0.67) KDM4EMEN1KMT2ARAB9ALPAR1
SCHEMBL6414136 0.82 KDM4E (0.47) LMNAKDM4EGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210052519-A1 Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation ACELOT,INC (US) 2021-02-25 US disclosed
US-20190210959-A1 Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation ACELOT, INC. 2019-07-11 US disclosed
US-4977144-A ADENOSINE AGONISTS CIBA-GEIGY CORPORATION (US) 1990-12-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190210959-A1 Small molecule drugs and related methods for treatment of diseases related to abeta42 oligomer formation APP, PSEN2, PSEN1 LMNA 635/4885KDM4E 4863/4885GAA 401/4885
US-20210052519-A1 Small molecule drugs and related methods for treatment of diseases related to tdo-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation HTT, TARDBP, SNCA LMNA 1330/4885KDM4E 4369/4885GAA 540/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.